Brii Bio HBV Trial Results

Brii Biosciences announced end-of-treatment results from its Phase 2b ENRICH and ENHANCE studies for chronic hepatitis B virus (HBV) infection. The ENRICH study, evaluating BRII-179 as a priming therapy, showed promising hepatitis B surface antigen (HBsAg) loss rates of 42.9% and 40.0%, consistent with prior findings and supporting its immune priming role. These results have led to preliminary alignment with the Center for Drug Evaluation of the China — National Medical Products Administration of China for a potential registrational study. In contrast, the ENHANCE study, which evaluated a concurrent triple combination, did not demonstrate improved HBsAg loss rates compared to previous cohorts, though it did show higher rates than the control arm. The company plans to present detailed data later in 2026. A significant challenge for Brii Biosciences is an ongoing arbitration with Vir Biotechnology concerning the elebsiran manufacturing technology transfer, which makes the future of the elebsiran program uncertain and prevents investment in a Phase 3 clinical study until resolved.